Panacea Biotec sees production of 1 bln doses of COVID-19 vaccine candidate in 2022

Panacea Biotec

08/07/2020 10:40

BENGALURU, July 8 (Reuters) - Indian biotech firm Panacea
Biotec Ltd  PNCA.NS  said on Wednesday it remains on schedule to
produce first production quantities of COVID-19 vaccine
candidate by January 2021.
    The company has production targets of 500 million doses for
2021 and one billion doses in 2022 for its COVID-19 vaccine
candidate, Panacea said in an emailed statement. 

    
     

 (Reporting by Anuron Kumar Mitra in Bengaluru; Editing by
Krishna Chandra Eluri)
 ((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))